Compare Moderna, Inc. (MRNA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PepsiCo, Inc. — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while PepsiCo, Inc. trades at $138.53 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 7.8× Moderna, Inc.'s market cap, and PepsiCo, Inc. pays a 4.28% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PEP | |
|---|---|---|
Market Cap | $24.18B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $81.80 | $170.44 |
52-Week Low | $22.36 | $134.95 |
Enterprise Value | $20.33B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
PepsiCo (PEP) trades at $138.22, up 0.38% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.20 beating expectations of $2.19, and robust profitability metrics including 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snacks and sponsorship changes, while analysts maintain a cautious but generally positive outlook.
PepsiCo presents a stable investment case with strong cash flow generation and dividend consistency, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $158.79 suggests 15% upside potential, supported by ongoing business optimization efforts. Key risks include consumer pushback on pricing and execution challenges in North American markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
